AnaptysBio Inc
Stock Chart, Company Information, and Scan Results
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
AnaptysBio Inc Company Information, Fundamentals, and Technical Indicators
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
AnaptysBio Inc In Our Stock Scanner
As of Nov 17, 2026Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.